You are here

Article Text

Article menu
Download PDFPDF
Letter
Risk of malignancy in patients treated for systemic necrotising vasculitis
  1. Antoine Lafarge1,2,
  2. Adrien Joseph3,
  3. Christian Pagnoux4,
  4. Xavier Puechal1,2,
  5. Pacal Cohen1,2,
  6. Maxime Samson5,
  7. Mohamed Hamidou6,
  8. Alexandre Karras7,
  9. Matthieu Groh1,
  10. Thomas Quemeneur8,
  11. Camillo Ribi9,
  12. Luc Mouthon1,2,10,
  13. Loic Guillevin1,2,10,
  14. Benjamin Terrier1,2,10
  15. on behalf of the French Vasculitis Study Group (FVSG)
  1. 1 Department of Internal Medicine, Cochin Hospital, Paris, France
  2. 2 National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
  3. 3 U1138, INSERM, Paris, France
  4. 4 Department of Rheumatology, Mount Sinai Hospital, Toronto, Ontario, Canada
  5. 5 Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, Dijon, France
  6. 6 Department of Internal Medicine, Hôtel Dieu, Nantes, France
  7. 7 Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France
  8. 8 Department of Internal Medicine, Hôpital de Valenciennes, Valenciennes, France
  9. 9 Department of Immunology, CHUV, Lausanne, Switzerland
  10. 10 Paris Descartes University, Paris, France
  1. Correspondence to Dr Antoine Lafarge, Internal Medicine, Hopital Cochin, Paris 75014, France; antoinelafarge{at}outlook.com; Pr Benjamin Terrier; benjamin.terrier{at}aphp.fr
View Full Text

http://dx.doi.org/10.1136/annrheumdis-2019-216452

Statistics from Altmetric.com

    Reduction in cyclophosphamide cumulative dose and introduction of newer immunosuppressive drugs may reduce the malignant burden of systemic necrotising vasculitis (SNV).1 2 This study aimed to describe malignancies recorded in five randomised controlled trials in SNV conducted by the French Vasculitis Study Group and to identify predictive factors.

    CHUSPAN, CHUSPAN 2, WEGENT, CORTAGE and MAINRITSAN trials evaluated different therapeutic strategies, summarised in online supplementary table S1, for the treatment of newly diagnosed or relapsing SNV. Informations regarding methods and references are provided in the online supplementary materials. The primary endpoint was the occurrence of malignancy.

    Supplemental material

    [annrheumdis-2019-216452supp001.pdf]

    A total of 733 patients included between 1993 and 2012 were pooled. Baseline characteristics of the population are summarised in table 1. During a 4485.9 person-years (PY) observation period, 39 (5.3%) patients developed malignancies (869.5 per 100 000 PY), including solid cancers in 34 (4.6%) cases (757.9 per 100000 PY) and haematological malignancies in 5 …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Correction notice This article has been corrected since it published Online First. The first author's name has been corrected.

    • Contributors LA and BT devised the project, the main conceptual ideas and proof outline, pooled and analysed data from the five randomised controlled trials (RCTs). AJ performed the statistical analysis. CP, XP, PC, CR, LG and BT designed and published the five RCTs involved in this article. LA and BT, wrote the manuscript. All authors discussed the results and contributed to the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.